

Patient Report

Rte: 00

Specimen ID: 104-988-9013-0

Control ID:

SAMPLE REPORT 1, 139900

Acct #: 90000999 **Phone:** (336) 436-8645

LabCorp Test Master
Test Account

5450 Millstream Road MCLEANSVILLE NC 27301

||կլլ||հունիրեկլիելի|||||||||||կլլ||-|||ել||ել||ել

Patient Details

DOB: 03/15/1959 **Age(y/m/d):** 062/00/30

Gender: M **Patient ID:**

Specimen Details

Date collected: 04/14/2021 0000 Local

Date received: 04/14/2021 **Date entered:** 04/14/2021

Date reported: 04/14/2021 0855 ET

Physician Details

Ordering: Referring: ID:

NPI:

General Comments & Additional Information

Clinical Info: NOT DETECTED

Ordered Items SARS-CoV-2, NAA

TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB

SARS-CoV-2, NAA

SARS-CoV-2, NAA Not Detected

Not Detected

01

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include RT-PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

SARS-CoV-2, NAA 2 DAY TAT

Performed 02

01	BN	LabCorp Burlington	Dir: Sanjai Nagendra, MD
		1447 York Court, Burlington, NC 27215-3361	
02	\$\$	Testmaster Testing	Dir: Report Testing, PhD
		3060 S Church Street, Burlington, NC 27215	

For inquiries, the physician may contact **Branch**: 800-222-7566 Lab: 336-436-2762



Patient Report

Specimen ID: 104-988-9014-0

Control ID:

SAMPLE REPORT 2, 139900

Acct #: 90000999 **Phone:** (336) 436-8645 Rte: 00

LabCorp Test Master **Test Account**

5450 Millstream Road

MCLEANSVILLE NC 27301

Patient Details

DOB: 02/02/1982 Age(y/m/d): 039/02/12

Gender: M **Patient ID:**

Specimen Details

Date collected: 04/14/2021 0000 Local

Date received: 04/14/2021 **Date entered:** 04/14/2021

Date reported: 04/14/2021 1443 ET

Physician Details

Ordering: Referring: ID:

NPI:

General Comments & Additional Information

Clinical Info: DETECTED

Ordered Items SARS-CoV-2. NAA

REFERENCE INTERVAL TESTS RESULT FLAG UNITS LAB SARS-CoV-2, NAA

SARS-CoV-2, NAA Detected Abnormal

Not Detected

01

Patients who have a positive COVID-19 test result may now have treatment options. Treatment options are available for patients with mild to moderate symptoms and for hospitalized patients. Visit our website at https://www.labcorp.com/COVID19 for resources and information.

This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include RT-PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

SARS-CoV-2, NAA 2 DAY TAT

Performed 02

01	BN	LabCorp Burlington	Dir: Sanjai Nagendra, MD
		1447 York Court, Burlington, NC 27215-3361	
02	\$\$	Testmaster Testing	Dir: Report Testing, PhD
		3060 S Church Street, Burlington, NC 27215	·

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762



Patient Report

Rte: 00

Specimen ID: 104-988-9015-0

Control ID:

SAMPLE REPORT 3, 139900

Acct #: 90000999 **Phone:** (336) 436-8645

LabCorp Test Master Test Account

5450 Millstream Road MCLEANSVILLE NC 27301

- ||Արլ||հունվորերը հոլիվ||||||||||Անդ-||ովհենինկիկը||ևե

Patient Details

DOB: 07/04/1976 **Age(y/m/d):** 044/09/10

Gender: M **Patient ID:**

Specimen Details

Date collected: 04/14/2021 0000 Local

Date received: 04/14/2021 **Date entered:** 04/14/2021

Date reported: 04/14/2021 0855 ET

Physician Details

Ordering: Referring: ID:

NPI:

General Comments & Additional Information

Clinical Info: INDETERMINATE

Ordered Items SARS-CoV-2. NAA

TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB
SARS-CoV-2, NAA

SARS-CoV-2, NAA Indeterminate Abnormal

Not Detected

01

We are UNABLE to reliably determine a result for the specimen due to the inconsistent amplification of all of the required SARS-CoV-2 components from the specimen submitted. If clinically indicated, please recollect an additional specimen for testing. This nucleic acid amplification test was developed and its performance characteristics determined by LabCorp Laboratories. Nucleic acid amplification tests include RT-PCR and TMA. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

SARS-CoV-2, NAA 2 DAY TAT

Performed 02

01	BN	LabCorp Burlington	Dir: Sanjai Nagendra, MD
02	\$\$	1447 York Court, Burlington, NC 27215-3361 Testmaster Testing	Dir: Report Testing, PhD
		3060 S Church Street, Burlington, NC 27215	

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762